A groundbreaking research has unveiled that Novo Nordisk’s NVO “miracle’ weight reduction drug Ozempic and related GLP-1 receptor agonists may considerably decrease the danger of alcohol and opioid overdoses.
This discovery suggests potential new functions for these medication, that are primarily used for treating weight problems and diabetes.
What Occurred: Analysis revealed within the journal Dependancy signifies that GLP-1 medication like Ozempic might play a vital position in lowering substance abuse, Monetary Occasions reported on Thursday.
The research examined information from over 500,000 people with opioid-use dysfunction and located that greater than 8,000 members who had been prescribed GLP-1 medication skilled a 40% discount in opioid overdose charges in comparison with these not on these medicines.
Moreover, amongst over 5,000 people with alcohol abuse points, these utilizing GLP-1 medication confirmed a 50% decrease price of intoxication.
See Additionally: SBC Medical Group Earnings Replace: H1 2024 Income Up 29% And Internet Earnings Up 123%
Fares Qeadan, an affiliate professor of biostatistics at Loyola College Chicago and the lead researcher, emphasised that these findings provide “vital preliminary proof” of the potential of GLP-1 receptor agonists in lowering overdose and intoxication charges.
Nonetheless, Matt Discipline from the UK’s Sheffield College cautioned that whereas these medication would possibly forestall extreme intoxication, they might not help customers in lowering or abstaining from substance use fully. The research’s conclusions are based mostly on digital well being data, and additional randomized managed trials are mandatory to determine a causal hyperlink.
Why It Issues: The potential of GLP-1 medication to deal with dependancy points is gaining consideration. A earlier research, revealed in JAMA Community Open in September, revealed that people with a historical past of opioid abuse who took Ozempic had been considerably much less prone to overdose.
This provides to the rising physique of proof suggesting that semaglutide, the energetic ingredient in Ozempic, may assist handle drug dependancy.
Furthermore, a research from March indicated that Ozempic and Wegovy might decrease the danger of creating hashish use dysfunction or relapse. These findings spotlight the potential of GLP-1 medication to deal with numerous substance use issues, providing new hope within the battle towards dependancy.
Learn Subsequent:
Picture through Shutterstock
This story was generated utilizing Benzinga Neuro and edited by Pooja Rajkumari
Market Information and Information dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
